What is Myaderm?
Myaderm operates at the intersection of pharmaceutical-grade skincare and pain management, specializing in the development of advanced transdermal CBD creams. By focusing on fast-acting formulations, the company addresses critical needs for individuals suffering from chronic and neuropathic pain, while simultaneously expanding its footprint in the anti-aging and dermatological care markets. Their product architecture is built upon a foundation of FDA-compliant manufacturing standards, ensuring that each topical application meets rigorous quality benchmarks. Through strategic partnerships with national retailers, Myaderm has successfully transitioned from a niche startup to a recognized brand, effectively bridging the gap between traditional wellness products and specialized therapeutic treatments.
How much funding has Myaderm raised?
Myaderm has raised a total of $297K across 2 funding rounds:
Debt
$150K
Debt
$147K
Debt (2020): $150K with participation from PPP
Debt (2021): $147K led by PPP
Key Investors in Myaderm
PPP
Public-Private Partnership
What's next for Myaderm?
With this late-stage funding secured, Myaderm is well-positioned to accelerate its market penetration and refine its product development pipeline. The strategic focus will likely shift toward expanding its retail distribution network and investing in clinical validation to further differentiate its offerings in a crowded marketplace. As the company matures, the emphasis on maintaining high-quality standards while scaling production will be paramount to sustaining its competitive advantage. Future growth initiatives may include the exploration of new therapeutic applications for its proprietary transdermal delivery systems, potentially opening doors to broader medical and wellness segments. By maintaining its focus on efficacy and consumer trust, Myaderm is poised to remain a significant player in the evolving landscape of cannabinoid-based therapeutics.
See full Myaderm company page
